These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2020610)

  • 1. Respiratory tract penetration of quinolone antimicrobials: a case in study.
    Ritrovato CA; Deeter RG
    Pharmacotherapy; 1991; 11(1):38-49. PubMed ID: 2020610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Penetration of danofloxacin into the respiratory tract tissues and secretions in calves.
    Friis C
    Am J Vet Res; 1993 Jul; 54(7):1122-7. PubMed ID: 8396371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic pharmacokinetic considerations in pulmonary infections.
    Cunha BA
    Semin Respir Infect; 1991 Sep; 6(3):168-82. PubMed ID: 1754737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of tissue penetration of antibiotics in the respiratory tract.
    Lambert HP
    Scand J Infect Dis Suppl; 1978; (14):262-6. PubMed ID: 279980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 6. [The efficacy of doxycycline in the treatment of respiratory infections (doxycycline levels in the serum, saliva, sputum, lung and pleural fluids) (author's transl)].
    Simon C; Sommerwerck D; Friehoff J
    Prax Klin Pneumol; 1978 Apr; 32(4):266-70. PubMed ID: 643799
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 8. Ofloxacin concentrations in tissues involved in respiratory tract infections.
    Perea EJ
    J Antimicrob Chemother; 1990 Nov; 26 Suppl D():55-60. PubMed ID: 2286591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
    Fujita A; Miya T; Tanaka R; Hirayama S; Isaka H; Ono Y; Koshiishi Y; Goya T
    Jpn J Antibiot; 1999 Nov; 52(11):661-6. PubMed ID: 10659442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The penetration of novel intravenous cephalosporins into the lung.
    Baldwin DR
    J Chemother; 1996 Feb; 8 Suppl 2():71-82. PubMed ID: 8738849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections.
    Koizumi F; Ohnishi A; Takemura H; Okubo S; Kagami T; Tanaka T
    Antimicrob Agents Chemother; 1994 May; 38(5):1140-3. PubMed ID: 8067752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secretion of ofloxacin into saliva in patients with respiratory tract infection.
    Takagi K; Hasegawa T; Yamaki K; Suzuki K; Nabeshima T
    Int J Clin Pharmacol Ther Toxicol; 1992 Feb; 30(2):46-50. PubMed ID: 1551745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rufloxacin (MF-934): in vitro and in vivo antibacterial activity.
    Ravizzola G; Pinsi G; Pirali F; Colombrita D; Foresti I; Peroni L; Turano A
    Drugs Exp Clin Res; 1989; 15(1):11-5. PubMed ID: 2743869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous followed by oral ofloxacin in the treatment of community acquired lower respiratory tract infections in adults requiring hospitalisation.
    Liam CK; Aziah AM; Lim KH; Wong CM
    Med J Malaysia; 2000 Sep; 55(3):304-7. PubMed ID: 11200708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of fluoroquinolones in lower respiratory tract infections.
    Vellend H
    Clin Invest Med; 1989 Feb; 12(1):39-43. PubMed ID: 2920482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of penetration and clearance of mezlocillin in the bronchopulmonary tract.
    Braga PC; Marchi E; Scaglione F; Scarpazza G; Faravelli M; Fraschini F
    Int J Clin Pharmacol Res; 1984; 4(5):361-5. PubMed ID: 6519850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases.
    Fraschini F; Braga PC; Cosentina R; Salvini P; Cortelazzi R; Scarpazza G; Scaglione F; Trazzi R; Odero A
    Int J Clin Pharmacol Res; 1987; 7(1):63-71. PubMed ID: 3583489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Penetration of cefotaxime into bronchial secretions].
    Bergogne-Berezin E; Morel C; Pierre J; Monrocq N; Dournovo P; Benard Y
    Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):501-5. PubMed ID: 6289226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
    Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H
    Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of ofloxacin versus cefazolin in lower respiratory tract infections.
    Bariffi F; Giacomelli P; Sanduzzi A; Perna F; De Masi AL
    Int J Clin Pharmacol Res; 1987; 7(3):199-201. PubMed ID: 3474212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.